| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Nov 14, 2017 | EBS Emergent Biosolutions Inc. | El-Hibri Fuad | Chairman | Sell | 40,000 | $40.37 | $1,614,800.00 | -1.3% | |
| Nov 13, 2017 | BCRX Biocryst Pharmaceuticals Inc | Sheridan William P67 | Senior VP - CMO | Sell | 64,310 | $4.72 | $303,543.20 | -72.9% | |
| Nov 13, 2017 | TLPH Talphera, Inc. | Asadorian Raffi | Chief Financial Officer | Buy | 5,000 | $1.94 | $9,710.50 | +71.4% | |
| Nov 10, 2017 | PCRX Pacira Biosciences, Inc. | Kronenfeld Mark A. | Director | Buy | 1,000 | $41.60 | $41,602.50 | +17.3% | |
| Nov 10, 2017 | LLY Eli Lilly & Co | Zulueta Alfonso G | SVP &President, Lilly Int'l | Sell | 2,003 | $83.67 | $167,591.01 | -4.4% | |
| Nov 10, 2017 | IRWD Ironwood Pharmaceuticals Inc | Consylman Gina | Interim CFO And CAO | Sell | 864 | $15.20 | $13,132.80 | -1.6% | |
| Nov 9, 2017 | AMPH Amphastar Pharmaceuticals, Inc. | Shohet Stephen B. | Director | Sell | 7,862 | $18.55 | $145,844.98 | -9.0% | |
| Nov 8, 2017 | MRK Merck & Co., Inc. | Glocer Thomas H | Director | Sell | 5,000 | $56.20 | $280,982.50 | -49.5% | |
| Nov 8, 2017 | NBIX Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 30,000 | $74.58 | $2,237,343.00 | -27.9% | |
| Nov 8, 2017 | EBS Emergent Biosolutions Inc. | Zoon Kathryn C62 | Director | Sell | 2,742 | $39.20 | $107,490.28 | -6.4% | |
| Nov 8, 2017 | ALKS Alkermes Plc. | Frates James M83 | SVP, Alks Inc; CFO Alks | Sell | 20,932 | $47.58 | $996,009.45 | -12.7% | |
| Nov 7, 2017 | EBS Emergent Biosolutions Inc. | Joulwan George A | Director | Sell | 14,251 | $41.24 | $587,711.24 | -19.0% | |
| Nov 7, 2017 | AMPH Amphastar Pharmaceuticals, Inc. | Gerst Diane G. | EVP, Qa &Regulatory Affairs | Sell | 523 | $17.93 | $9,375.30 | -1.6% | |
| Nov 3, 2017 | EBS Emergent Biosolutions Inc. | Abdun-Nabi Daniel | President &CEO | Sell | 31,508 | $42.77 | $1,347,490.00 | -7.2% | |
| Nov 2, 2017 | NBIX Neurocrine Biosciences Inc | Obrien Christopher Flint | Chief Medical Officer | Sell | 52,817 | $69.71 | $3,681,640.68 | -35.0% | |
| Nov 2, 2017 | ALKS Alkermes Plc. | Pops Richard F57 | Director And CEO, Alkermes Plc | Sell | 50,000 | $48.87 | $2,443,410.00 | -7.3% | |
| Nov 2, 2017 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 24,818 | $71.05 | $1,763,318.90 | -14.5% | |
| Nov 2, 2017 | AMPH Amphastar Pharmaceuticals, Inc. | Shohet Stephen B. | Director | Sell | 7,862 | $18.37 | $144,459.53 | -24.6% | |
| Nov 1, 2017 | ALKS Alkermes Plc. | Landine Michael J | SVP, Corp Dev., Alkermes, Inc. | Sell | 15,000 | $48.71 | $730,687.50 | -8.4% | |
| Nov 1, 2017 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,000 | $49.16 | $49,160.00 | -11.1% | |
| Oct 26, 2017 | AMPH Amphastar Pharmaceuticals, Inc. | Shohet Stephen B. | Director | Sell | 7,862 | $18.39 | $144,618.35 | -24.6% | |
| Oct 24, 2017 | ANIK Anika Therapeutics, Inc. | Sherwood Charles H | CEO And Director | Sell | 3,278 | $60.04 | $196,811.12 | -2.4% | |
| Oct 24, 2017 | AMPH Amphastar Pharmaceuticals, Inc. | Gerst Diane G. | EVP, Qa &Regulatory Affairs | Sell | 523 | $18.29 | $9,567.61 | -1.5% | |
| Oct 24, 2017 | LFCR Lifecore Biomedical, Inc. \de\ | Hemmeter Molly | Chief Executive Officer | Sell | 7,399 | $13.06 | $96,658.94 | -7.0% | |
| Oct 23, 2017 | ANIK Anika Therapeutics, Inc. | Sherwood Charles H | CEO And Director | Sell | 28,219 | $60.06 | $1,694,713.32 | -8.7% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.